tradingkey.logo

Cytek Biosciences Inc

CTKB
查看詳細走勢圖
5.100USD
+0.030+0.59%
收盤 12/26, 16:00美東報價延遲15分鐘
652.11M總市值
虧損本益比TTM

Cytek Biosciences Inc

5.100
+0.030+0.59%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.59%

5天

+3.03%

1月

-8.93%

6月

+43.66%

今年開始到現在

-21.42%

1年

-20.19%

查看詳細走勢圖

TradingKey Cytek Biosciences Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Cytek Biosciences Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名59/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.75。中期看,股價處於上升通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Cytek Biosciences Inc評分

相關信息

行業排名
59 / 207
全市場排名
168 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
5.750
目標均價
+18.31%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Cytek Biosciences Inc亮點

亮點風險
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
業績高增長
公司營業收入穩步增長,連續3年增長22.20%
估值高估
公司最新PE估值-49.67,處於3年歷史高位
機構減倉
最新機構持股80.93M股,環比減少0.00%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉438.00股

Cytek Biosciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Cytek Biosciences Inc簡介

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
公司代碼CTKB
公司Cytek Biosciences Inc
CEOJiang (Wenbin)
網址https://cytekbio.com

常見問題

Cytek Biosciences Inc(CTKB)的當前股價是多少?

Cytek Biosciences Inc(CTKB)的當前股價是 5.100。

Cytek Biosciences Inc 的股票代碼是什麼?

Cytek Biosciences Inc的股票代碼是CTKB。

Cytek Biosciences Inc股票的52週最高點是多少?

Cytek Biosciences Inc股票的52週最高點是7.300。

Cytek Biosciences Inc股票的52週最低點是多少?

Cytek Biosciences Inc股票的52週最低點是2.370。

Cytek Biosciences Inc的市值是多少?

Cytek Biosciences Inc的市值是652.11M。

Cytek Biosciences Inc的淨利潤是多少?

Cytek Biosciences Inc的淨利潤為-6.02M。

現在Cytek Biosciences Inc(CTKB)的股票是買入、持有還是賣出?

根據分析師評級,Cytek Biosciences Inc(CTKB)的總體評級為買入,目標價格為5.750。

Cytek Biosciences Inc(CTKB)股票的每股收益(EPS TTM)是多少

Cytek Biosciences Inc(CTKB)股票的每股收益(EPS TTM)是-0.103。
KeyAI